048410.KQ实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 14:30):

Hyundai Bioscience Co., Ltd., a biotechnology company, develops and commercializes bio-fusion technology for delivering active ingredients to human body...

Stats
今日成交量	211 771
平均成交量	470 669
市值	808.31B
EPS	KRW0 ( 2024-02-25 )
下一个收益日期	( KRW0 ) 2024-05-13
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW50.50 (0.25%)

音量相关性

長: -0.11 (neutral)

短: -0.17 (neutral)

Signal:(53.603) Neutral

Hyundai Bioscience Co., 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Hyundai Bioscience Co., 相关性 - 货币/商品

-0.15
( neutral )

-0.16
( neutral )

0.06
( neutral )

-0.01
( neutral )

-0.47
( neutral )

0.06
( neutral )

Hyundai Bioscience Co., 财务报表

Annual	2023
营收:	KRW9.48B
毛利润:	KRW3.92B (41.36 %)
EPS:	KRW-364.53

FY	2023
营收:	KRW9.48B
毛利润:	KRW3.92B (41.36 %)
EPS:	KRW-364.53

FY	2022
营收:	KRW7.85B
毛利润:	KRW1.95B (24.79 %)
EPS:	KRW-401.53

Financial Reports:

No articles found.

Hyundai Bioscience Co.,

Hyundai Bioscience Co., Ltd., a biotechnology company, develops and commercializes bio-fusion technology for delivering active ingredients to human body. The company provides Vitabrid C12, a new-conceptual vitamin C product that delivers active vitamin C into the skin. It also develops organic-inorganic hybrid technology, a drug delivery system technology that allows the selective and effective delivery of active substances on the target area in combination with bio-friendly minerals, as well as in anticancer drug carrier technology. The company was founded in 2000 and is based in Seoul, South Korea.